Trial
NCT03701711
Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Ohio State University
Collaborators
Celgene Corporation; University of Michigan
Condition
Demyelinating Sensorimotor Neuropathy
Intervention
Lenalidomide
Why stopped
Higher than expected occurrence of VTE (venous thromboembolic event)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-27